Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.

The study confirms the effectiveness of ETA even for re-treatment of patients with JIA. Our data highlight the association of an early bDMARD treatment with a higher rate of inactive disease indicating a window of opportunity.